


I hereby certify that this correspondence is being  
Facsimile transmitted to the United States Patent  
and Trademark Office on March 27, 2007.



Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. § 121  
Examining Group 1649  
Patent Application  
Docket No. G-194US03PCT  
Serial No. 10/519,335

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Olga N. Chernyshev  
Art Unit : 1649  
Applicants : Laurent Cavarec, Ilya Chumakov, Benoit Destenaves, Catherine Gonthier,  
Isabelle Elias  
Serial No. : 10/519,335  
Filed : December 22, 2004  
Conf. No. : 9318  
For : Novel KCNQ Polypeptides, Modulators Thereof, and their Uses in the  
Treatment of Mental Disorders

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

ELECTION UNDER 35 U.S.C. § 121

Sir:

In response to the written Restriction Requirement dated February 27, 2007 in the above-identified patent application, Applicants hereby elect to prosecute the invention of Group I (claims 50-52 and 54-60) and the polypeptide of SEQ ID NO: 2, without traverse.

Prior to examination, Applicants respectfully request that the subject application be amended as follows: